Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.

Glen Lo; H Al Zahrani; HJ Jang; R Menezes; J Hudson; P Burns; Mairead Mcnamara; S Kandel; K Khalili; Jennifer Knox; P Rogalla; TK Kim

doi:10.1016/j.ultrasmedbio.2016.01.025

Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.

Glen Lo, H Al Zahrani, HJ Jang, R Menezes, J Hudson, P Burns, Mairead Mcnamara, S Kandel, K Khalili, Jennifer Knox, P Rogalla, TK Kim

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

85 Downloads (Pure)

Abstract

This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. Twenty patients were enrolled (aged 18-78 y; median 65). DCE-US was performed with bolus injection and infusion/disruption replenishment. Median overall survival was 7.1 mo (1.8-27.3) and progression free survival was 3.6 mo (1.8-17.4). Fifteen patients completed infusion scans and 12 completed bolus scans at 2 wk. Among the perfusion parameters, fractional blood volume at infusion (INFBV) decreased at 2 wk in 10/15 (16%-81% of baseline, mean 47%) and increased in 5/15 (116%-535%, mean 220%). This was not significantly associated with progression free survival (p = 0.310) or progression at 16 wk (p = 0.849), but was borderline statistically significant (p = 0.050) with overall survival, limited by a small sample size. DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed.

Original language	English
Pages (from-to)	1303-1311
Journal	Ultrasound in Medicine and Biology
Volume	42
Issue number	6
Early online date	28 Mar 2016
DOIs	https://doi.org/10.1016/j.ultrasmedbio.2016.01.025
Publication status	Published - Jun 2016

Keywords

dynamic contrast-enhanced ultrasound, hepatocellular carcinoma, liver neoplasms, axitinib, tumor response, perfusion

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ultrasmedbio.2016.01.025

2016-11-19-DCEUS Axitinib HCCAccepted author manuscript, 106 KB

Cite this

Lo, G., Al Zahrani, H., Jang, HJ., Menezes, R., Hudson, J., Burns, P., Mcnamara, M., Kandel, S., Khalili, K., Knox, J., Rogalla, P., & Kim, TK. (2016). Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. Ultrasound in Medicine and Biology, 42(6), 1303-1311. https://doi.org/10.1016/j.ultrasmedbio.2016.01.025

@article{8fb01232aeb54fb1ac4cf99096187e1e,

title = "Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.",

abstract = "This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. Twenty patients were enrolled (aged 18-78 y; median 65). DCE-US was performed with bolus injection and infusion/disruption replenishment. Median overall survival was 7.1 mo (1.8-27.3) and progression free survival was 3.6 mo (1.8-17.4). Fifteen patients completed infusion scans and 12 completed bolus scans at 2 wk. Among the perfusion parameters, fractional blood volume at infusion (INFBV) decreased at 2 wk in 10/15 (16%-81% of baseline, mean 47%) and increased in 5/15 (116%-535%, mean 220%). This was not significantly associated with progression free survival (p = 0.310) or progression at 16 wk (p = 0.849), but was borderline statistically significant (p = 0.050) with overall survival, limited by a small sample size. DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed.",

keywords = "dynamic contrast-enhanced ultrasound, hepatocellular carcinoma, liver neoplasms, axitinib, tumor response, perfusion",

author = "Glen Lo and {Al Zahrani}, H and HJ Jang and R Menezes and J Hudson and P Burns and Mairead Mcnamara and S Kandel and K Khalili and Jennifer Knox and P Rogalla and TK Kim",

year = "2016",

month = jun,

doi = "10.1016/j.ultrasmedbio.2016.01.025",

language = "English",

volume = "42",

pages = "1303--1311",

journal = "Ultrasound in Medicine and Biology",

issn = "0301-5629",

publisher = "Elsevier BV",

number = "6",

}

Lo, G, Al Zahrani, H, Jang, HJ, Menezes, R, Hudson, J, Burns, P, Mcnamara, M, Kandel, S, Khalili, K, Knox, J, Rogalla, P & Kim, TK 2016, 'Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.', Ultrasound in Medicine and Biology, vol. 42, no. 6, pp. 1303-1311. https://doi.org/10.1016/j.ultrasmedbio.2016.01.025

TY - JOUR

T1 - Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.

AU - Lo, Glen

AU - Al Zahrani, H

AU - Jang, HJ

AU - Menezes, R

AU - Hudson, J

AU - Burns, P

AU - Mcnamara, Mairead

AU - Kandel, S

AU - Khalili, K

AU - Knox, Jennifer

AU - Rogalla, P

AU - Kim, TK

PY - 2016/6

Y1 - 2016/6

N2 - This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. Twenty patients were enrolled (aged 18-78 y; median 65). DCE-US was performed with bolus injection and infusion/disruption replenishment. Median overall survival was 7.1 mo (1.8-27.3) and progression free survival was 3.6 mo (1.8-17.4). Fifteen patients completed infusion scans and 12 completed bolus scans at 2 wk. Among the perfusion parameters, fractional blood volume at infusion (INFBV) decreased at 2 wk in 10/15 (16%-81% of baseline, mean 47%) and increased in 5/15 (116%-535%, mean 220%). This was not significantly associated with progression free survival (p = 0.310) or progression at 16 wk (p = 0.849), but was borderline statistically significant (p = 0.050) with overall survival, limited by a small sample size. DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed.

AB - This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. Twenty patients were enrolled (aged 18-78 y; median 65). DCE-US was performed with bolus injection and infusion/disruption replenishment. Median overall survival was 7.1 mo (1.8-27.3) and progression free survival was 3.6 mo (1.8-17.4). Fifteen patients completed infusion scans and 12 completed bolus scans at 2 wk. Among the perfusion parameters, fractional blood volume at infusion (INFBV) decreased at 2 wk in 10/15 (16%-81% of baseline, mean 47%) and increased in 5/15 (116%-535%, mean 220%). This was not significantly associated with progression free survival (p = 0.310) or progression at 16 wk (p = 0.849), but was borderline statistically significant (p = 0.050) with overall survival, limited by a small sample size. DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed.

KW - dynamic contrast-enhanced ultrasound, hepatocellular carcinoma, liver neoplasms, axitinib, tumor response, perfusion

U2 - 10.1016/j.ultrasmedbio.2016.01.025

DO - 10.1016/j.ultrasmedbio.2016.01.025

M3 - Article

SN - 0301-5629

VL - 42

SP - 1303

EP - 1311

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

IS - 6

ER -

Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound.

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this